SAI Life Sciences Ltd. (IN:SAILIFE)
:SAILIFE
Want to see IN:SAILIFE full AI Analyst Report?
SAILIFE Stock Chart & Stats
₹1010.25
₹4.05(0.56%)
At close: 4:00 PM EST
₹1010.25
₹4.05(0.56%)
Day’s Range― - ―
52-Week Range₹704.45 - ₹1,243.00
Previous CloseN/A
Volume67.81K
Average Volume (3M)11.95K
Market Cap
₹250.36B
Enterprise Value₹247.72B
Total Cash (Recent Filing)₹3.06B
Total Debt (Recent Filing)₹5.64B
Price to Earnings (P/E)73.8
Beta1.09
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.01
Shares Outstanding212,115,160
10 Day Avg. Volume10,862
30 Day Avg. Volume11,945
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)8.20
Price to Sales (P/S)9.29
P/FCF Ratio-282.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,270.00Price Target Upside25.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)19.54
Revenue Forecast (FY)₹26.60B
Bulls Say, Bears Say
Bulls Say
Integrated CRDMO ModelSAI's integrated CRDMO model provides discovery, process R&D and API manufacturing under one roof, enabling multi-stage engagements. This fosters customer stickiness, cross-selling and multi-year program economics, supporting durable fee-based revenue and higher lifetime value per client.
Strong Revenue And Margin MomentumSharp revenue growth with expanding EBIT and net margins indicates scalable operations and improving mix toward higher-value development work. Sustained top-line momentum plus operating leverage supports long-term profitability improvement if demand and mix remain stable.
Conservative Balance Sheet And Rising ROELow leverage and a materially higher ROE improve financial flexibility to fund capacity, R&D or selective M&A without stressing solvency. A stronger equity base and prudent debt levels support durable investment capacity and resilience through pharma demand cycles.
Bears Say
Persistently Negative Free Cash FlowDespite accounting profits, the company has posted negative free cash flow for consecutive years. Persistent FCF deficits reduce the ability to internally fund expansion or return capital, increasing reliance on external financing or equity to support growth initiatives.
Weak Cash Conversion Despite Operating Cash GainsOperating cash improved materially, yet free cash flow stayed negative, implying heavy capex or working-capital absorption. If cash conversion does not stabilize, funding needs may constrain margins, limit reinvestment pacing or force higher external financing costs long term.
Gross Margin PressureA decline in gross margin signals possible input-cost increases or pricing pressure in competitive markets. Sustained erosion at the gross level can compress operating profits and limit the upside from operating leverage unless offset by pricing power or productivity gains.
SAI Life Sciences Ltd. News
SAILIFE FAQ
What was SAI Life Sciences Ltd.’s price range in the past 12 months?
SAI Life Sciences Ltd. lowest stock price was ₹704.45 and its highest was ₹1243.00 in the past 12 months.
What is SAI Life Sciences Ltd.’s market cap?
SAI Life Sciences Ltd.’s market cap is ₹250.36B.
When is SAI Life Sciences Ltd.’s upcoming earnings report date?
SAI Life Sciences Ltd.’s upcoming earnings report date is Aug 06, 2026 which is in 53 days.
How were SAI Life Sciences Ltd.’s earnings last quarter?
SAI Life Sciences Ltd. released its earnings results on May 14, 2026. The company reported ₹4.9 earnings per share for the quarter, missing the consensus estimate of ₹5.1 by -₹0.2.
Is SAI Life Sciences Ltd. overvalued?
According to Wall Street analysts SAI Life Sciences Ltd.’s price is currently Undervalued.
Does SAI Life Sciences Ltd. pay dividends?
SAI Life Sciences Ltd. does not currently pay dividends.
What is SAI Life Sciences Ltd.’s EPS estimate?
SAI Life Sciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SAI Life Sciences Ltd. have?
SAI Life Sciences Ltd. has 212,115,160 shares outstanding.
What happened to SAI Life Sciences Ltd.’s price movement after its last earnings report?
SAI Life Sciences Ltd. reported an EPS of ₹4.9 in its last earnings report, missing expectations of ₹5.1. Following the earnings report the stock price went up 2.42%.
Which hedge fund is a major shareholder of SAI Life Sciences Ltd.?
Currently, no hedge funds are holding shares in IN:SAILIFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SAI Life Sciences Ltd.
Sai Life Sciences Ltd. operates as a Contract Research, Development, and Manufacturing Organization (CRDMO), providing services to clients both in India and internationally. Its offerings include expertise in medicinal chemistry, pharmacokinetic analysis, manufacturing processes, and various contract development solutions. The company was initially known as SAI Advantium Pharma Limited before it was rebranded as Sai Life Sciences Limited in July 2006. Established in 1999, the firm's main base of operations is in Hyderabad, India.
SAILIFE Stock 12 Month Forecast
Average Price Target
₹1,270.00
▲(25.71% Upside)
Technical Analysis
Jubilant Pharmova Limited
―
Laurus Labs Ltd.
―
Neuland Laboratories Ltd.
―
Piramal Pharma Limited
―
Syngene International Ltd.
―